276 F. Supp. 3d 629
E.D. Tex.2017Background
- UroPep sued Eli Lilly for induced infringement of U.S. Patent No. 8,791,124 (the ’124 patent), claiming Lilly’s marketing and sale of Cialis (tadalafil) for BPH induced infringement of claim 1 (a method of administering a selective PDE5 inhibitor to treat BPH). A jury found infringement and awarded $20 million. Lilly moved for JMOL and a new trial; the court denied the motion.
- The ’124 patent (priority date July 9, 1997) claims use of an "inhibitor of phosphodiesterase (PDE) V" (construed at trial as a selective PDE5 inhibitor: ≥20× selective for PDE5 over PDE1–4). The specification lists preferred selective inhibitors (10 specific compounds + 2 classes), but tadalafil is not among the named preferred compounds; the issued claim excludes eight listed compounds (to avoid double patenting), thereby leaving tadalafil within claim scope.
- Trial evidence: (1) the FDA label for Cialis states tadalafil is >20× selective for PDE5 and that 5 mg is effective for BPH; (2) extensive Lilly marketing for BPH; (3) expert testimony and inventor testimony about discovery of PDE1/4/5 in prostate and tissue-relaxation experiments; (4) evidence that hundreds of selective PDE5 inhibitors (including tadalafil) were known by 1997.
- Lilly litigated four primary invalidity defenses (written description, enablement, anticipation, obviousness) plus indefiniteness and challenged several claim constructions and evidentiary rulings; the jury rejected Lilly’s defenses. Lilly additionally moved to exclude certain documentary evidence and challenged the court’s jury instructions.
- The court reviewed legal standards (Rule 50/59 and Federal Circuit/Fifth Circuit precedents), applied fact-intensive analyses to each invalidity defense, and concluded substantial evidence supported the jury verdict; denied JMOL and new trial requests.
Issues
| Issue | Plaintiff's Argument (UroPep) | Defendant's Argument (Lilly) | Held |
|---|---|---|---|
| Written description (genus "selective PDE5 inhibitor") | Spec discloses representative species and common structural/physical features; field was mature so prior art + specification suffice to show possession. | Spec fails to describe sufficient representative species or structural features for the broad genus (tadalafil not named); negative claim limitations unexplained. | Court: Jury could reasonably find written description adequate; prior art and specification together supported genus; negative limitation permissible and tied to prosecution. JMOL/new trial denied. |
| Enablement (practicing full claim scope without undue experimentation) | Patent and incorporated methods (assays, fractionation) plus routine industry screening enable a skilled artisan to identify/selectivity and dose-range; FDA-level development not required. | Practicing the full genus would require undue, unpredictable experimentation; dose-setting and bioavailability issues mean claim not enabled. | Court: Credible expert testimony supported enablement; routine experimentation was sufficient; Lilly failed to meet clear-and-convincing burden. JMOL/new trial denied. |
| Obviousness | Inventors discovered PDE5 presence/function in prostate; prior art did not teach PDE5 in prostate or use of selective PDE5 inhibitors for BPH; objective indicia supported nonobviousness. | Prior knowledge that relaxing smooth muscle treats BPH and that PDE5 inhibitors relax smooth muscle made claim obvious. | Court: Substantial evidence supports jury finding nonobvious; prior art did not teach PDE5 presence/role in prostate and Burnett (1995) taught away. JMOL/new trial denied. |
| Anticipation / Printed-publication (Cheung monograph) | N/A (plaintiff) | Monograph described herb(s) containing a weak PDE5 inhibitor and BPH benefit—thus anticipates. Also argued monograph was a printed publication. | Court: Jury could reasonably find Cheung did not disclose an "effective amount" of a PDE5 inhibitor and was not established as a printed publication accessible to skilled artisans pre‑priority. JMOL/new trial denied. |
Key Cases Cited
- Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (written-description standard: specification must show possession of claimed invention from skilled‑artisan perspective)
- LizardTech, Inc. v. Earth Res. Mapping, Inc., 424 F.3d 1336 (Fed. Cir. 2005) (specification need not spell out every detail where prior art supplies necessary understanding)
- Capon v. Eshhar, 418 F.3d 1349 (Fed. Cir. 2005) (no rigid requirement to disclose a representative species where prior art and context supply necessary information)
- In re Wands, 858 F.2d 731 (Fed. Cir. 1988) (Wands factors govern undue experimentation/enablement inquiry)
- Wyeth v. Abbott Labs., 720 F.3d 1380 (Fed. Cir. 2013) (enablement may fail where art is unpredictable and specification gives no guidance)
- Boston Sci. Corp. v. Johnson & Johnson, 647 F.3d 1353 (Fed. Cir. 2011) (written description invalid where specification lacked structure/examples and art was nascent/unpredictable)
- Nautilus, Inc. v. Biosig Instruments, Inc., 134 S. Ct. 2120 (U.S. 2014) (indefiniteness requires claims inform skilled artisan with reasonable certainty)